Your session is about to expire
← Back to Search
PET-MR Imaging with [18F]F-AraG for HIV Infection
Study Summary
This trial is exploring the use of a new PET tracer to study HIV in the body. It will enroll people who are early or late in their infection, or who are not on treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have severe HIV-related infections like pneumonia or brain infections.I have an active autoimmune disease.I have HIV and am either on ART, have never been on ART, or haven't taken ART for at least a month.I have not had any vaccines in the last 14 days.I am HIV positive and either started ART, never had ART, or stopped ART at least a month ago.My kidneys work well, with a creatinine clearance rate of 60 mL/min or more.I haven't had immune therapy in the last 60 days, except for an HIV vaccine.My kidney function, measured by creatinine clearance, is good.I am a woman who can have children, not pregnant, and use two birth control methods.I have a history of heart failure that needed treatment.I am not pregnant and can be tested to confirm.I haven't been hospitalized or needed IV antibiotics in the last 3 months.I currently have hepatitis C or had it but was successfully treated.I have been diagnosed with myelodysplasia syndrome or had lymphoproliferative disease.I am older than 18 years.I am older than 18 years.
- Group 1: [18F]F-AraG
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment for this research project still open?
"Affirmative. Clinicaltrials.gov indicates that this clinical study, initially posted on September 21st 2018, is actively recruiting patients for participation. To complete the trial, 30 individuals need to be collected from one medical centre."
Is the FDA's approval necessary to administer [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)?
"The safety of [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine) is rated a 1 by Power's team, due to the limited efficacy and safety data collected from Phase I trials."
How many people are currently participating in this research endeavor?
"Affirmative, clinicaltrials.gov indicates that this clinical experiment is presently recruiting candidates. This trial was first advertised on September 21st 2018 and has had its details updated most recently on June 28th 2022. The study requires 30 participants to be recruited from a single site."
Share this study with friends
Copy Link
Messenger